Stock ARTL ARTELO BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Artelo Biosciences, Inc.

Equities

ARTL

US04301G5080

Market Closed - Nasdaq
Other stock markets
 21:30:00 16/05/2024 BST 		5-day change 1st Jan Change
1.36 USD +3.02% Intraday chart for Artelo Biosciences, Inc. -2.16% -2.86%
04-23 Transcript : Artelo Biosciences, Inc. - Special Call
04-23 Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
AQ
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
AQ
Transcript : Artelo Biosciences, Inc. - Special Call
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
AQ
Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
CI
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
AQ
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
AQ
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
AQ
Top Premarket Gainers
MT
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
AQ
Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
CI
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
AQ
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
AQ
Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
AQ
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
AQ
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARTL Stock
  4. News Artelo Biosciences, Inc.